Sign In
Buy GLP
$49.49
+1.02 (+2.10%)
At Close: Jul 08, 2026
3 High Growth GLP-1 Biotech Winners to Buy in July
08:00am, Thursday, 09'th Jul 2026
The GLP-1 trade has matured from a single-stock story into a tiered opportunity set.
Wall Street Is Betting on Eli Lilly's GLP-1 Portfolio — It's Missing the $1 Trillion Opportunity
12:02pm, Wednesday, 08'th Jul 2026
The pharmaceutical industry is entering a new era where biology and artificial intelligence are converging.
Novo Nordisk shares dip as latest prescription data points to GLP-1 pill slowdown
10:39am, Wednesday, 08'th Jul 2026
Shares in Novo Nordisk (NYSE:NVO) fell 2.5% to DKK319.20 after Deutsche Bank pointed to a continued slowdown in the oral version of the company's Wegovy weight-loss drug in the US. The bank published
Eli Lilly and Novo Nordisk Are Fine -- but These 2 Stocks Could Be an Even Better Way to Invest in the GLP-1 Boom
05:30pm, Tuesday, 07'th Jul 2026
Becton, Dickinson supplies equipment whose demand is soaring due to the rise of GLP-1 medicines. Abbott Laboratories' most important growth driver could benefit from greater adoption of GLP-1 drugs.
Eli Lilly Stock Hits a New All-Time High: Has It Gotten Too Expensive to Buy?
11:00am, Tuesday, 07'th Jul 2026
Eli Lilly's growth rate has been accelerating over the past year due to its GLP-1 drugs. The recent approval of its GLP-1 pill, Foundayo, could offer yet another catalyst.
Kailera's GLP-1 drug meets main goal of late-stage trials
07:09am, Tuesday, 07'th Jul 2026
Kailera Therapeutics said on Tuesday its GLP-1 drug for patients with diabetes and obesity met the main goal of two-late stage trials.
Nestle to Tweak Some Food Recipes to Appeal to Duller GLP-1 Palates
06:32am, Tuesday, 07'th Jul 2026
Nestle is looking to spice up some of its products to counter duller taste buds that can accompany GLP-1 weight-loss drugs.
Oil's 31% Q2 Selloff Opens the Door to 3 Strong Buy Stocks
09:01am, Monday, 06'th Jul 2026
Lower crude prices have reset energy-sector expectations, making GLP, NESR and IMO buy candidates for investors seeking oil-linked opportunities.
BetterLife Engages Nucro-Technics to Complete the last GLP Toxicology Study of BETR-001 Required by the FDA for IND and Phase 1
08:00am, Monday, 06'th Jul 2026
Vancouver, British Columbia--(Newsfile Corp. - July 6, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company") announces it has entered into an agreemen
BioNxt Advances GLP-1 Sublingual Semaglutide ODF Program with Next Stage of Delivery Development Underway
03:05am, Monday, 06'th Jul 2026
VANCOUVER, BC / ACCESS Newswire / July 6, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery syste
Can Medicare Bridge Help Novo Nordisk Defend Its GLP-1 Leadership?
10:16am, Friday, 03'rd Jul 2026
NVO benefits from Medicare's GLP-1 Bridge, but equal coverage for rival therapies shifts the obesity race toward clinical differentiation and long-term outcomes.
Eli Lilly Hits Highs on GLP-1 Medicare Inclusion, Huge Results
10:23am, Wednesday, 01'st Jul 2026
Eli Lilly and Company (LLY) shares up 18,585% since Big Money bought big in 1990.
Weight Loss ETFs Poised to Rally as Medicare Greenlights GLP-1 Coverage
09:16am, Wednesday, 01'st Jul 2026
Medicare's new GLP-1 coverage could expand access to weight-loss drugs, making ETFs a diversified way to tap growth across the obesity treatment market.
Viking Therapeutics: Updating Pipeline Potential As Oral GLP‑1s Accelerate
02:32pm, Tuesday, 30'th Jun 2026
Viking Therapeutics, Inc. maintains a Hold rating, reflecting a balanced risk-reward at its current ~$5B valuation amid sector momentum. Novo Nordisk's oral Wegovy launch sets a new benchmark, highlig
Can Eli Lilly's New Drugs Fuel Growth Beyond Its GLP-1 Blockbusters?
11:25am, Tuesday, 30'th Jun 2026
LLY is expanding its revenue base beyond Mounjaro and Zepbound with new launches and label expansions that can strengthen long-term growth.
